Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.

Lloyd A, Vickery ON, Laugel B.

Front Immunol. 2013 Aug 5;4:221. doi: 10.3389/fimmu.2013.00221. eCollection 2013.

2.

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh N, Shi J, June CH, Ruella M.

Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7. Review.

PMID:
29039115
3.

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA.

PLoS One. 2010 Jul 22;5(7):e11726. doi: 10.1371/journal.pone.0011726.

4.

Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.

Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Kammula US.

Cancer Res. 2015 Aug 15;75(16):3216-26. doi: 10.1158/0008-5472.CAN-15-0584. Epub 2015 Jun 22.

5.

Genetic approaches for antigen-selective cell therapy.

Alvarez-Vallina L.

Curr Gene Ther. 2001 Nov;1(4):385-97. Review.

PMID:
12109064
6.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
7.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Review.

PMID:
25901860
8.
9.

Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ.

J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. doi: 10.1016/j.jamcollsurg.2011.12.034. Epub 2012 Feb 22.

10.

Application of Genome Editing Techniques in Immunology.

Zych AO, Bajor M, Zagozdzon R.

Arch Immunol Ther Exp (Warsz). 2018 Jan 17. doi: 10.1007/s00005-018-0504-z. [Epub ahead of print] Review.

PMID:
29344676
11.

Genome-Edited T Cell Therapies.

Delhove JMKM, Qasim W.

Curr Stem Cell Rep. 2017;3(2):124-136. doi: 10.1007/s40778-017-0077-5. Epub 2017 Apr 18. Review.

12.

T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!

Porter DL, June CH.

Bone Marrow Transplant. 2005 May;35(10):935-42. Review.

PMID:
15806121
13.

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.

16.

Development of adoptive cell therapy for cancer: a clinical perspective.

Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium.

Hum Gene Ther. 2010 Jun;21(6):665-72. doi: 10.1089/hum.2010.086. Review.

PMID:
20408760
17.

Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM.

Clin Cancer Res. 2008 Jun 15;14(12):3966-74. doi: 10.1158/1078-0432.CCR-08-0356.

18.

Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.

Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M.

PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820. Epub 2013 Feb 18.

19.

siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.

van der Waart AB, Fredrix H, van der Voort R, Schaap N, Hobo W, Dolstra H.

Cancer Immunol Immunother. 2015 May;64(5):645-54. doi: 10.1007/s00262-015-1668-6. Epub 2015 Feb 28.

20.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925

Supplemental Content

Support Center